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A myriad of innovative bispecific antibody (BsAb) platforms have been reported. Most require significant protein
engineering to be viable from a development and manufacturing perspective. Single-chain variable fragments (scFvs)
and diabodies that consist only of antibody variable domains have been used as building blocks for making BsAbs for
decades. The drawback with Fv-only moieties is that they lack the native-like interactions with CH1/CL domains that
make antibody Fab regions stable and soluble. Here, we utilize a redesigned Fab interface to explore 2 novel Fab-based
BsAbs platforms. The redesigned Fab interface designs limit heavy and light chain mixing when 2 Fabs are co-
expressed simultaneously, thus allowing the use of 2 different Fabs within a BsAb construct without the requirement of
one or more scFvs. We describe the stability and activity of a HER2£HER2 IgG-Fab BsAb, and compare its biophysical
and activity properties with those of an IgG-scFv that utilizes the variable domains of the same parental antibodies. We
also generated an EGFR £ CD3 tandem Fab protein with a similar format to a tandem scFv (otherwise known as a
bispecific T cell engager or BiTE). We show that the Fab-based BsAbs have superior biophysical properties compared to
the scFv-based BsAbs. Additionally, the Fab-based BsAbs do not simply recapitulate the activity of their scFv
counterparts, but are shown to possess unique biological activity.
Introduction
Genomic and proteomic profiling have provided evidence of
the complexity of multifaceted diseases such as cancer and auto-
immunity. Targeted therapeutics such as monoclonal antibodies
(mAbs) typically intervene in single molecular pathways.
Although they have provided substantial benefits in various dis-
eases, many targeted therapeutics have limited efficacy or durabil-
ity in complex diseases. For example, the multiplicity of genetic
alterations and strong mutagenic potential of many cancers
allows them to circumvent targeted pathway inhibition.1-3 Thera-
pies that provide more complex mechanisms of disease interven-
tion may enable enhanced efficacy. Bispecific antibodies (BsAbs)
are an emerging class of therapeutics that may fulfill this need
because they allow the engagement of multiple targets and more
complex intervention mechanisms.4,5
Recombinant DNA technologies have enabled the generation
of many different types of BsAbs. Some of the common BsAb
formats are made possible through the use of single chain Fv
(scFv) building blocks 6 taken from existing mAb therapeutics or
discovered using in vitro screening methodologies. The Fv region
contains the antigen recognition domains (VH and VL) of a mAb
and tethers them together using a flexible or structured linker.
BsAbs formats using scFvs or disulfide bonded Fvs include tan-
dem scFvs (often used as bispecific T cell engagers or ‘BiTEs’),
tetravalent IgG-scFvs, diabodies, and many other formats.7-10 An
issue with these Fv moieties is that they lack the native Fab (anti-
gen binding fragment) architecture found within the majority of
mammalian immunoglobulins. The native architecture provides
the stabilizing interactions of heavy and light chain constant
domains, CH1 and CL, respectively.
11,12 The lack of these stabi-
lizing domains can lead to compromised thermal stability or sol-
ubility and an increased potential for aggregation within BsAbs
containing isolated Fv fragments.12,13
Replacement of the commonly used scFv moiety with a more
stable Fab moiety may make these BsAb formats more stable and
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well-behaved. Recently, we generated a novel Fab interface that
enabled 2 Fab moieties to be expressed simultaneously without
heavy chain (HC)/light chain (LC) mixing.14 We demonstrated
the use of this methodology for generating BsAbs with native-like
IgG architecture.14 Here, we utilize these Fab interface designs to
enable the expression and correct assembly of IgG-Fab (instead of
IgG-scFv) and tandem Fab (instead of tandem scFv) BsAbs. Such
multivalent molecules have been described previously, but only
with monospecific constructs.15 The bispecific versions of these
formats lead to HC/LC mispairing, but this problem can be miti-
gated using the Fab interface designs.14 We demonstrate the
robust biophysical properties of these BsAbs and their potential
utility in various oncology applications.
Results
Construction and assembly of an IgG-Fab BsAb against HER-2
The most common tetravalent bispecific platforms are the IgG-
scFv 8,16-19 and DVD-Ig.20,21 Both formats contain Fv regions
stripped from their natural VH_CH1/VL_CL Fab format. We
wished to evaluate an IgG-Fab BsAb similar to the IgG-scFv BsAb
(Fig. 1A). IgG-Fab BsAbs require a 3 chain transfection (HC, LC1,
and LC2) compared to the other tetravalent formats that require an
antibody-like 2 chain transfection. For proof-of-concept, we wished
to combine the activities of trastuzumab (HerceptinTM) and pertu-
zumab (PerjetaTM), which were approved for use as combination
therapy in 2013 in advanced metastatic HER-2-positive breast
cancer.22
We built an IgG-Fab BsAb containing the LC specificity
designs described previously 14 and an IgG-scFv BsAb for com-
parison. We chose to utilize pertuzumab as the N-terminal Fab
or scFv and trastuzumab as the IgG based on a previous study
that evaluated the orientational effects of N-terminal and C-ter-
minal fusions of pertuzumab and trastuzumab.23 Both molecules
expressed at levels comparable to their parental mAbs in the tran-
sient HEK293F system (Life Technologies). The BsAbs were
purified using a single affinity chromatography step and charac-
terized by analytical size exclusion chromatography (SEC) with
in-line static light scattering (SEC-LS). The IgG-scFv BsAb had
the expected molecular mass of 200 kDa based on static light
scattering measurements and demonstrated a propensity to form
aggregates. The IgG-Fab had the expected molecular mass of
250 kDa and was monodisperse with low aggregates similar to
IgG control proteins (Fig. 1B). Differential scanning calorimetry
(DSC) studies of the 2 BsAbs demonstrated that the pertuzumab
scFv within the IgG-scFv unfolded at a lower temperature (Tm
(midpoint of unfolding) D 57C) than the pertuzumab Fab
within the IgG-Fab (Tm D 70C, Fig. 1C). To evaluate whether
the LCs were assembled properly within the IgG-Fab, we ana-
lyzed the protein using intact mass spectrometry (MS) where the
molecular mass of the entire oxidized molecule is determined.
The protein had the molecular weight expected for 2 HCs, 2 tras-
tuzumab LCs, and 2 pertuzumab LCs (Fig. 2A). To specifically
demonstrate that the LCs correctly bound their cognate HC Fd
regions (i.e., VH_CH1), we engineered a Factor Xa-specific
cleavage site between the N-terminal Fab and the IgG of the
IgG-Fab BsAb. The IgG-Fab BsAb was cleaved using Factor Xa
and analyzed by MS. The Fab and IgG regions of the spectrum
were found to contain the correct LC/Fd pairing (Fig. 2B), indi-
cating that the LC specificity designs were successful in directing
the LCs to the correct HC Fd.
Activity of anti-HER-2 IgG-Fab BsAb
To confirm the tetravalent binding activity of the IgG-Fab
and IgG-scFv BsAbs, we performed solution-based competition
studies using surface plasmon resonance (SPR). Since the BsAbs
both comprise mAbs directed toward HER-2, we separately
tested the BsAbs’ ability to inhibit HER-2 binding to sensorchip
surfaces labeled with pertuzumab IgG1 or trastuzumab IgG1.
The assay format enables measurement of the stoichiometry of
inhibition, which is a gauge of the valency of each BsAb toward
each epitope. The pertuzumab and trastuzumab IgG1s could
only block binding to matched sensorchip surfaces and actually
Figure 1. (A) Schematic diagrams of pertuzumab and trastuzumab IgG1
and the pertuzumab £ trastuzumab IgG-Fab and IgG-scFv BsAbs. Notice
the N-terminal Fab of the IgG-Fab contains a fully intact pertuzumab Fab
with VH, VL, CH1, and CL, while the N-terminal scFv contains only a VH and
VL domain of pertuzumab. (B) Analytical SEC of the IgG-scFv and IgG-Fab
BsAbs after expression in 293F cells and a single step protein A purifica-
tion. (C) DSC results with the HER2 £ HER2 IgG-Fab (bottom) and IgG-scFv
(top). The unfolding events of the various domains within the 2 molecules
are annotated. The Fc (CH2 and CH3) unfolding events for IgG1 are well
characterized.47 The trastuzumab and pertuzumab Fab unfolding curves
were characterized previously 14 and their unfolding events within the
IgG-Fab can be deduced based on the data with the monoclonal antibod-
ies. For the IgG-scFv, one of the variable domains of pertuzumab unfolds
at a much lower Tm resulting from the lack of the CH1/CL domains, a trait
typical of scFvs.12
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led to increased signal when combined with HER-2 antigen and
tested on the orthogonal surface, likely the result of simultaneous
binding of soluble IgG and surface-bound IgG to HER-2 antigen
(Fig. 3A, B). The pertuzumab IgG appeared to inhibit HER-2
binding to its own surface at a valency slightly above the BsAbs
(»11 nM), but within experimental error. Both the IgG-Fab
and IgG-scFv BsAbs demonstrated a slope of inhibition of
»17 nM in the presence of 40 nM HER-2 on both the pertuzu-
mab (Fig. 3A) and trastuzumab (Fig. 3B) sensorchip surfaces
indicative of tetravalent activity. The fact that all inhibition
curves hit the x-axis at competitor concentrations slightly less
than 20 nM is likely due to the HER-2 concentration being
slightly off or the HER-2 protein not being fully intact. Both the
IgG-Fab and IgG-scFv BsAbs also demonstrated a shallow
increase in signal on the sensorchip surfaces with increased con-
centration. When titrating the IgG-Fab and IgG-scFv BsAbs
onto the sensorchip surfaces in the absence of HER-2, we observed
a shallow association with the pertuzumab and trastuzumab sur-
faces (and not to a control IgG1 surface) that increased with
BsAb concentration and roughly matched the high concentration
signals observed in the presence of HER-2 (Fig. 3A, B).
The BsAbs were tested for their ability to inhibit the in vitro
growth of the HER-2 positive N87 gastric cancer cell line in the
presence of cell culture media and 10% fetal bovine serum (FBS)
over a 5 day period. Both pertuzumab and trastuzumab led to mod-
est (30–40%) decreases in N87 cell growth and the mAb combina-
tion enhanced the inhibition (50%, Fig. 3C). The IgG-scFv BsAb
did not inhibit cell growth, although in repeat experiments we
observed signals for the IgG-scFv as high as the parental mAbs. The
IgG-Fab dramatically decreased cell growth (»80%) at the saturated
dose as did a described previously IgG BsAb that combined the per-
tuzumab and trastuzumab parental IgGs (Fig 3C).14
Construction and assembly of a tandem Fab BsAb against
epidermal growth factor receptor and CD3
Next, we utilized the Fab redesigns 14 to generate a novel tan-
dem Fab molecule. Tandem scFvs have been used for nearly
20 years to redirect T cells to target and kill other cell types using
antigens on their surfaces.24,25 These tandem scFvs (called bispe-
cific T cell engagers or BiTEs) have been validated in the clinic
with the most advanced being blinatumomab (BLINCYTO), a
CD19 £ CD3 BiTE approved in the US for the treatment of
Philadelphia chromosome-negative relap-sed or refractory B-cell
precursor acute lymphoblastic leukemia and in Phase 3 clinical
trials for refractory non-Hodgkin lymphoma.26,27 We wished to
see if a tandem Fab molecule would: 1) be more stable/manufac-
turable than a tandem scFv containing 2 separate scFvs each car-
rying the liabilities of scFv moieties; and 2) maintain the activity
of the tandem scFv format that has been proposed to work well
by ideally bridging the immune synapse between the T cell and
tumor cell through its relatively small molecular size.25 As a
proof-of-concept, we utilized the anti-epidermal growth factor
receptor (EGFR) mAb matuzumab 28 and an in-house anti-
human CD3e mAb to generate both a tandem Fab and a tandem
scFv that could be compared and contrasted against one another
(Fig. 4A). The tandem scFv was built with the anti-EGFR scFv
at the N-terminus connected to the anti-CD3 scFv via a 5 amino
acid G4S linker designed to disfavor inappropriate VH/VL mis-
pairing. The tandem Fab was built to assemble as a 3 chain con-
struct with 2 LCs expressed separately and the 2 HC Fds (VH
Figure 2. (A) Intact mass analysis of the IgG-Fab BsAb (aglycosyl). The
expected molecular weight was observed for containing 2 pertuzumab
LCs, 2 trastuzumab LCs, and 2 HCs. The inset is a zoomed in view of the
intact IgG-Fab peak. Visible is a 3% impurity of material containing 1 per-
tuzumab LC and 3 trastuzumab LCs denoted mispair#1 or ‘MP1.’ Also
shown is the expected molecular weight for material containing 3 pertu-
zumab LCs and 1 trastuzumab LC denoted ‘MP2’with an arrow pointing
to where it would be expected on the graph. (B) To show that the LCs
bound the proper HC Fd region, we utilized an engineered FXa site
between the N-terminal pertuzumab Fab and the trastuzumab IgG to
cleave them apart. Intact mass analysis found only properly HC/LC
assembled fragments. The insets are zoomed in views of the intact pertu-
zumab Fab and intact trastuzumab IgG fragments to demonstrate their
purity. The arrow attached to ‘MP3’ points to the expected molecular
weight of a pertuzumab Fd fragment with a mispaired trastuzumab LC.
The arrow attached to ‘MP4’ shows the expected molecular weight of a
trastuzumab IgG with a mispaired pertuzumab LC. No evidence of MP3
nor MP4 was observed.
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and CH1) expressed as a single chain with a (G4S)3 linker
between the 2 Fd regions. The EGFR Fd was at the N-terminus.
The upper hinge (IgG1) was included in both Fd regions of the
tandem Fab to allow covalent linkage with the LCs. Both con-
tained C-terminal 8£histidine tags (on the HC for the tandem
Fab).
The tandem Fab and tandem scFv production was very differ-
ent. Both were expressed transiently in HEK293F. The tandem
Fab expressed well and was >98% monomer directly off a histag
affinity resin with a 35 mg/L purified yield that needed no fur-
ther purification. The tandem scFv expressed modestly and con-
tained 17% aggregates (mostly dimer/trimer) directly off the
histag affinity resin. Lower molecular weight peaks were also
apparent – some of them
putatively cleavage products
of the tandem scFv. The tan-
dem scFv was further puri-
fied by preparative SEC with
a final purified yield of
4.4 mg/L (8-fold lower than
the tandem Fab). Analytical
SEC chromatograms of the
final purified forms of the
tandem Fab and tandem
scFv are shown in Fig. 4B.
MS analyses of the tandem
Fab and tandem scFv were
performed to confirm that
they were both intact. Both
were found to have their
expected molecular weights
(Fig. 4C, D). Roughly 6%
of the tandem Fab (based on
detector counts) was found
to contain 2 anti-CD3 LCs
instead of both the anti-
EGFR and anti-CD3 LCs.
The thermal stability of the
tandem scFv was also signifi-
cantly lower than what was
observed for the tandem Fab
based on temperature-
induced unfolding moni-
tored by circular dichroism
(CD) (Fig. 4E). Both BsAbs
exhibited apparent single
unfolding transitions com-
prising the unfolding of all
the protein domains. The
Tm of the tandem scFv was
56.7C, and the Tm of the
tandem Fab was 73.6C if
fit to a 2-state transition,29
although the unfolding was
almost certainly not revers-
ible or 2-state. Thus, the
expression, purity, and thermal stability of the tandem Fab was
superior to that of the tandem scFv.
Activity of EGFR£CD3 tandem Fab and tandem scFv
BsAbs
Next, we evaluated the binding activity of the EGFR£CD3
tandem Fab and tandem scFv BsAbs. Kinetic SPR was used to
evaluate the binding to CD3 and EGFR separately. Each was
found to have equivalent binding kinetics to the 2 antigens
(Fig. 5, Table 1). Therefore, binding kinetics are unlikely to be a
discriminating factor between the biological activity of the 2 for-
mats. A low level of heterogeneous binding was observed for the
EGFR kinetics, which led to imperfections in the fits with both
Figure 3. (A and B) Solution-based binding and stoichiometry studies with the HER2xHER2 BsAbs. (A) Titration of
IgGs and BsAbs evaluating their ability to block soluble HER-2 binding to a sensor chip surface labeled with pertu-
zumab. The initial velocity (Vi, y-axis) is the initial slope of binding (initial 40 seconds) of HER-2 in the presence of
mAb or BsAb and is a measure of the free HER-2 concentration. (B) Same experiment except the sensorchip surface
was labeled with trastuzumab. (C) Inhibition of N87 gastric cancer cell growth by the parental trastuzumab and per-
tuzumab IgGs, a combination of the IgGs, the IgG-Fab BsAb and the IgG-scFv BsAb.
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BsAbs. Possible explanations could be non-specific binding or
differential folding/epitope exposure within the EGFR extracellu-
lar domain protein (Fig. 5B, D). Similar, but exaggerated, het-
erogeneity was observed when using commercial human EGFR-
Fc (R&D systems, data not shown).
The tandem Fab and tandem scFv BsAbs were tested for their
ability to redirect activated T cells to kill tumor cells. T cells from
a healthy human donor were purchased and cultured in the pres-
ence of anti-CD3, anti-CD28 and IL-2 for at least 5 days for
activation. The CD4/CD8 profile of the activated T cells as well
as markers of their activation (CD69/CD25) is provided in
Table 2. The BsAbs, the parental mAbs (anti-CD3 and anti-
EGFR), as well as the combination of the parental mAbs were
separately mixed with activated T cells and applied to A431
tumor cells, which were measured using a QuantiBRITE assay to
have an average of 160,000 cell surface EGF receptors per cell.14
The ability of the tandem
Fab BsAb to redirect the
activated T cells to kill the
tumor cells was assessed
using 2 separate methods.
The first method used CSFE
labeling of the tumor cells
followed by incubation with
the T cells/tandem Fab
BsAb or control mAbs for
12 hours followed by FACS
analysis using 7-aminoacti-
nomycin (7-AAD) to visual-
ize dead or dying tumor
cells. A small trend toward
slightly higher killing was
observed with the anti-CD3
mAb (alone or in combina-
tion) over the control IgG,
perhaps the result of non-
BsAb-mediated T cell killing
(Fig. 6A). The EGFR£CD3
tandem Fab resulted in sig-
nificantly greater tumor cell
killing (»80%) compared to
the controls demonstrating
its ability to redirect activated
T cells to kill the tumor cells
(Fig. 6A).
Next, the tandem Fab
and tandem scFv BsAbs
were titrated in the presence of the activated T cells and their
redirected lysis activity was assessed using a tumor cell viability
assay. Both BsAbs redirected T cells to kill the tumor cells with
high potency; however, the apparent potency was roughly 10-
fold better for the tandem scFv (EC50 < 10 pM for the tandem
scFv vs. <100 pM for the tandem Fab, Fig. 6B). One small dif-
ference between the tandem scFv and tandem Fab was the length
of the linker sequence between the scFvs (G4S)1 and the Fabs
(G4S)3. We shortened the tandem Fab linker to (G4S)1 and
expressed, purified and tested its redirected lysis activity. Modifi-
cation of the linker length within the tandem Fab had no effect
on the potency of the tandem Fab redirected lysis activity (data
not shown).
The tandem Fab and tandem scFv BsAbs were further tested
for their ability to recruit and activate bulk non-stimulated T cells
in the presence of tumor cells. In this study, untreated T cells
Figure 4 (see previous page). (A) Schematic diagrams of the matuzumab (anti-EGFR) IgG1 mAb, in-house anti-CD3 IgG1agly (N297Q mutation) mAb,
and the EGFR £ CD3 tandem Fab and tandem scFv BsAbs. (B) Analytical SEC of the purified BsAbs along with an IgG1 control mAb. The tandem Fab was
purified using a single step Ni2C-NTA affinity chromatography step, while the tandem scFv required the affinity step along with a preparative SEC step to
remove aggregates and lower molecular weight cleavage products. (C and D) Intact mass analyses of the tandem Fab and tandem scFv, respectively.
The inserts show a zoomed in view of the intact proteins demonstrating the purity. A 6% impurity within the tandem Fab, which contained 2 anti-CD3
LCs. (E) Thermal unfolding profiles of the EGFR£CD3 tandem Fab () and tandem scFv (^) BsAbs monitored by CD. Even though both BsAbs could have
multiple unfolding transitions, they both displayed only one that could be fit using a 2-state approximation to obtain Tm. The tandem Fab exhibited a Tm
of 73.6C while the tandem scFv exhibited a Tm of 56.7C.
Figure 5. (A–D) Binding of soluble, monomeric CD3eg and EGFR extracellular domains (3 to 50 nM) to immobilized
tandem Fab (A, B) and tandem scFv (C, D), respectively, using SPR. Each concentration was run in duplicate and
the curves were fit to a 1:1 binding model to derive ka, kd, and KD.
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from a healthy human donor were thawed and immediately
mixed with either the BsAbs or control mAbs just prior to their
addition to A431 cells. After 48 hours of incubation, the viability
of the tumor cells and the activated status of the T cells were eval-
uated. Both BsAbs led to strong activation in the majority of T
cells based on increased CD69/CD25 expression (Fig. 7A,
Table 2). A minority of the T cells demonstrated CD69 upregu-
lation (early activation) within both the anti-CD3 and anti-
CD3/anti-HER-2 combination arms, likely due to the bivalent
nature of the aglycosyl anti-CD3 mAb (Fig. 7A, Table 2). Only
the BsAbs led to significant tumor cell lysis via T cell recruitment
and activation (Fig. 7B). Low level T cell activation by anti-CD3
alone did not lead the T cells to kill A431 tumor cells. We
included an EGFR£CD3 IgG BsAb described previously 14 into
the assay. While each of the BsAbs demonstrated equivalent
binding kinetics to both EGFR and CD3, the BsAb format
appeared to significantly effect BsAb potency.
Discussion
One of the goals of the current study was to compare the bio-
physical properties of BsAbs using Fab moieties versus those
using scFvs to gain the multiple specificities. The ability to specif-
ically direct HC/LC assembly when co-expressing 2 Fab moieties
14 enables the use of Fabs as the building block of BsAbs com-
pared to the commonly used scFv. The stability and solubility
benefit provided to the VH/VL domains by the CH1/CL domains
has been described in many reports 12 and a dissection of the sta-
bilizing effects was performed by Rothlisberger and coworkers.11
We show that even with substantial changes to the interface
within the Fab moiety based on the Fab designs,14 the Fab moie-
ities within both the IgG-Fab and tandem Fab BsAbs are substan-
tially more thermally stable than their scFv counterparts within
the IgG-scFv and tandem scFv BsAbs. Like common IgGs, the
Fab-based BsAbs showed little to no propensity to form aggre-
gates, while the scFv-based BsAbs both demonstrated significant
tendencies toward aggregation. Attenuated stability and a pro-
pensity to aggregate is likely linked to the tandem scFv’s poor
expression. Based on their biophysical superiority over scFv-based
BsAbs, we believe Fab-based BsAbs will be an attractive avenue as
therapeutic agents.
Many new anti-CD3-based BsAbs with varied formats are
demonstrating the ability to redirect and activate T cells to target
tumors expressing the tumor antigen of the BsAb. The most
common BsAb format for redirecting T cells to lyse target cells is
the tandem scFv because it is thought to recapitulate the immune
synapse endogenously formed between T cells and target cell
MHC proteins.30,31 Other dual Fv-based moieties like Dual-
Affinity Re-Targeting (DART) molecules are thought to derive
their activity and potency through a similar mechanism.32 New
BsAb formats with very different geometries have recently shown
their utility for T cell activation/redirected lysis such as bivalent,
bispecific IgGs and others.33,34 Here, we show that tandem Fab
anti-CD3 BsAbs have the capacity to redirect and activate T cells
to kill antigen presenting cells. T cell redirection and tumor cell
lysis are not necessarily linked as shown by anti-CD8 or anti-
CD4-based BsAbs described recently that can redirect activated
T cells to kill tumor cells, but cannot activate them on their
own.35 The ability to activate the T cells along with redirecting





















Tandem Fab 6.2e5 5.7e-3 9.2 2.2e5 3.2e-3 15
Tandem scFv 3.9e5 4.2e-3 10.7 1.5e5 1.9e-3 13
Table 2. T cell activation by the BsAbs in the presence of tumor cells
Immune Cell Source CD3% CD8%c CD4%c CD69% CD25%
Donor T cells activated for 5 days using anti-CD3/anti-CD28/IL-2 97.8 75.8 38.6 98.1
97.8 22.2 64.2 98.4
Donor bulk T cells (non-treated) 71.9 0.49 2.06
21.4 1.27 0.42
Donor bulk T cells, A431 tumor cells, EGFR£CD3 tandem Fab 70.8 63.2 45.73
21.9 66.6 42.78
Donor bulk T cells, A431 tumor cells, EGFR£CD3 tandem scFv 72 66.3 52.3
21.2 69.6 52.67
Donor bulk T cells, A431 tumor cells, anti-CD3 mAbb and anti-EGFR mAb 66 20.1 1.68
21.6 17.8 0.68
Donor bulk T cells, A431 tumor cells, anti-CD3 mAbb 72 21.53 1.48
20.7 22.48 0.91
Donor bulk T cells, A431 tumor cells, anti-EGFR mAb 71.3 0.19 0.087
20.6 0.51 0.015
Donor bulk T cells, A431 tumor cells, IgG1 control mAb 72.9 0.15 0.086
20.4 0.96 0.021
aAll BsAbs and mAbs in the flow cytometry experiment were held at 1 nM.
bAnti-CD3 mAb was human IgG1 with an N297Q mutation to remove glycosylation and reduce FcgR binding.
cData on the top of each row is from CD4C T cells. Data on the bottom of each row is from CD8C T cells.
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them appears to be a property of targeting CD3e, which is an
invariant subunit of the T cell receptor complex.
Lastly, the Fab-based BsAbs did not simply recapitulate the
activity of scFv-based BsAbs. In both approaches investigated
here, the Fab-based BsAbs
had different biological
activity than their scFv-
based counterparts. For the
HER-2£HER-2 combina-
tion, the IgG-Fab inhibited
N87 tumor cell growth to a
significantly greater extent
than the IgG-scFv. The
ability to inhibit HER-2-
driven cell growth has been
shown to have a strong
dependence on the geome-
try and valence of engage-
ment.36 The HER-
2£HER-2 IgG-Fab was not
the first BsAb to show
enhanced efficacy over the
mAb combination; 14,37,38
however, it does highlight
the value of having access to
multiple BsAb formats such
as IgG BsAbs or IgG-Fab
for empirical testing of the
optimal geometry, valency,
and mAb combinations that
provide the desired activity




redirecting T cells to lyse
EGFR-expressing tumor
cells with the tandem scFv
BsAb (50 kDa) being
almost an order of magni-
tude more potent than the
tandem Fab BsAb
(100 kDa) and almost 2
orders of magnitude more
potent than the IgG BsAb
(150 kDa) even though the
BsAb binding kinetics to
EGFR and CD3 proteins
were equivalent. This does
lead one to speculate
whether the BsAb molecular
weight affects the intercellu-
lar distance and immune
synapse formation between
T cells and target cells.39
More data with varied epit-
opes and perhaps different antigens would help test this hypothe-
sis. Others have recently recognized the value of Fab-based BsAbs
as well. A recent study highlights the ability of the CrossMab
approach to generate IgG-Fabs targeting TNF and IL-17.40,41
Figure 6. (A) Flow cytometry histograms of the population of dead EGFRC A431 tumor cells (quadrant 2, Q2) after a
12 hour incubation in the presence of 100 nM of each article, mAb or BsAb, using a 15:1 E:T cell ratio. (B) Redirected
tumor cell lysis activity after a 5 hour incubation of A431 tumor cells with pre-activated T cells (1:10 ratio) monitored
with a cell viability assay. The BsAb curves were fit to a standard 4 parameter sigmoidal equation described in the
methods.
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New methods of attaining specificity of heavy chain/light chain
pairing have recently been reported with the potential to create
IgG-Fab or tandem Fab BsAbs.42,43 Overall, both the IgG-Fab
and tandem Fab BsAb formats have biophysical advantages over
their scFv-based counterparts and can be tested in parallel with
these BsAbs or other formats such as IgG BsAbs to more thor-
oughly and empirically test for the most desired therapeutic
outcomes.
Methods
Construction of test articles
The pertuzumab (anti-HER-2), trastuzumab (anti-HER-2)
and matuzumab (anti-EGFR) sequences were obtained from the
National Center for Biotechnology information (NCBI) and the
Rutgers Center for Structural Biology Protein Data Bank
(RCSB-PDB). The anti-human CD3 sequence was obtained
from an in-house clone. The IgG-Fab heavy chain coding DNA
sequence was generated in 2 pieces (Fab and IgG) using overlap-
ping PCR with pertuzumab and trastuzumab IgG constructs
already published.14,44 The 2 pieces were cloned into a mamma-
lian expression vector (Lonza) using a 3-way ligation using the
ClonablesTM Kit (Novagen) and existing HindIII (5’) and EcoRI
(3’) expression cassette restriction sites and an internal BamHI
site designed within the (G4S)5 linker region. The HER-
2£HER-2 IgG-scFv heavy chain was cloned the same way into
the same mammalian expression vector. For construction of the
EGFR£CD3 tandem Fab heavy chain and the entire
EGFR£CD3 tandem scFv, the entire coding DNA sequences
were generated using overlapping PCR and cloned directly into
the same mammalian expression construct using the HindIII and
Figure 7. (A) Flow cytometry histograms of CD69 and CD25 activation marker levels on CD8 positive T cells after a 48 hour incubation in the presence of
EGFR C A431 cells and 1 nM EGFR £ CD3 tandem Fab (left), Anti-CD3 IgG1 mAb (center), or an IgG1 control mAb (right). Numbers in each quadrant of
the histrograms indicate the relative population of cells displaying each marker or both markers (upper right). (B) The percent cell survival of A431 cells
incubated for 48 hours in the presence of various test articles and bulk (non-pretreated) T cells. Included in the assay was an IgG BsAb described previ-
ously.14 The lines between points were simple interpolations (no fit).
478 Volume 7 Issue 3mAbs
EcoRI restriction sites. The pertuzumab, trastuzumab, matuzu-
mab, and anti-CD3 light chains containing the Fab specificity
mutations were also synthesized via overlapping PCR and cloned
into the same mammalian expression plasmid using the same
restriction sites. All constructs utilized a murine kappa leader sig-
nal sequence that is cleaved upon secretion. All ligated constructs
were transformed into chemically competent TOP 10 E. coli cells
(Life Technologies). Colonies were picked, cultured, and the
plasmids were prepped (Qiagen MiniPrep kit). Correct sequences
were confirmed by in-house DNA sequencing.
Expression, purification, and biophysical characterization
The IgG-Fab and IgG-scFv plasmids were scaled up by trans-
formation in TOP10 E. coli, mixed with 100 mL Luria broth in
a 250 mL baffled flask and shaken overnight at 220 r.p.m. Large-
scale plasmid purifications were done using the BenchPro 2100
(Life Technologies) according to the manufacturer’s protocols.
Proteins were expressed in HEK293F cells using Freestyle trans-
fection reagents and protocols provided by the manufacturer
(Life Technologies). For the HER-2£HER-2 IgG-Fab, one HC
plasmid and 2 LC plasmids were co-transfected at 3 mg DNA
per 1 mL culture using a 1:1:1 ratio. For the HER-2£HER-2
IgG-scFv, one HC plasmid and one LC plasmid were co-trans-
fected at 2 mg DNA per 1 mL culture using a 1:2 ratio. For the
EGFR£CD3 tandem Fab, one HC plasmid and 2 LC plasmids
were co-transfected at 3 mg DNA per 1 mL culture using a 1:1:1
ratio. For the EGFR£CD3 tandem scFv, one plasmid containing
both scFvs was transfected using 2 mg DNA. Transfected cells
were grown at 37C in a 5% CO2 incubator while shaking at
125 r.p.m. for 5 days. Supernatants were harvested by centrifuga-
tion at 10 K r.p.m. for 5 minutes followed by passage through
2 mm filters.
Purification of the IgG-Fab and IgG-scFv was performed
using standard protein A affinity chromatography methods as
described previously.14 No second step of purification was per-
formed. Purification of the tandem Fab and tandem scFv BsAbs
was performed using standard Ni2C-nitrilo acidic acid-agarose
affinity chromatography on an AKTA Explorer (GE Healthcare).
The resin was equilibrated in PBS. Supernatants were directly
loaded onto the affinity column, washed with PBS, then eluted
with 10 column volumes of PBS C 500 mM imidazole, pH 7.4.
The tandem Fab was highly monodisperse after affinity chroma-
tography and required no further purification steps. For the tan-
dem scFv, the eluants were concentrated using a 10 kDa
centrifugal concentrator (Millipore) and loaded onto a PBS-
equilibrated 120 mL Superdex 75 column for aggregate and low
molecular weight cleavage product removal.
Analytical size exclusion chromatography with in-line light
scattering (SEC-LS), differential scanning calorimetry (DSC),
and mass spectrometry was performed as described previously.14
Factor Xa cleavage of the HER-2£Her-2 IgG-Fab
The HER2£HER-2 IgG-Fab was dialyzed in dialyzing buffer
containing 20 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl2 at
pH 8.0. Factor Xa (1 mL per 50 mg of IgG-Fab protein – New
England BioLabs) was added and incubated at 4C overnight to
cleave the Fab from the IgG. Factor Xa was removed by adding
100 ml of Xarrest agarose (EMD Millipore) per 8 mL Factor Xa
and incubated at room temperature for 1 hr. The resin was spun
down and the supernatant was collected. The resulting passed
through a 0.2 mm filter and analyzed directly by mass spectrom-
etry as described.44 The 2 proteins were further separated using
an IgSelect column (GE Healthcare) that specifically binds IgG-
Fc. Fab eluted in the flow-through. The IgG fraction was eluted
from the column with 100 mM glycine buffer at pH 3.2 and
neutralized using 1 M Tris buffer. The solution was dialyzed
against PBS prior to mass spectrometry analysis.
Stability measurements using automated circular dichroism
All CD experiments were performed on a Chirascan Plus
(Applied Photophysics) with a peltier sample heater, external
water bath heat sink, and an autosampling unit. The stability of
the EGFR£CD3 tandem Fab and tandem scFv were assessed by
thermally unfolding the proteins over a temperature range of 20–
100C. Wavelength scans from 250 to 198 nm were performed
every 1C of the temperature gradient. Scans used a 0.5 mm
cuvette, with a 1 nm step size and bandwidth and an averaging
time of 0.7 seconds. Both proteins were at 5 mM in PBS. Tem-
perature-dependent protein unfolding parameters were either
analyzed using the Global3 module of the dynamic multimode
spectroscopy software of the manufacturer or fit at a single wave-
length (235 nm) using a 2-state approximation.
Binding and stoichiometry measurements for HER2
(pertuzumab)£HER2(trastuzumab) IgG-Fab and IgG-scFv
BsAbs
Solution Biacore experiments were designed as described pre-
viously.18,45 All experiments were performed on a Biacore3000
(GE Healthcare). Pertuzumab and trastuzumab (generated in-
house) 14 were diluted to 20 mg/mL in 10 mM Acetate, pH 5
and immobilized to separate CM5 sensorchip surfaces at a high
level (»12000 resonance units, RUs) using standard amine cou-
pling protocols provided by the manufacturer (GE Healthcare).
Binding of 25 nM soluble HER-2 (speed BioSystems) was per-
formed at 2 mL/min to fall within the mass transfer arena and a
strong signal (»500 RU) was achieved after 3 minutes of injec-
tion. The concentration of unbound HER-2 in the presence of
varying concentrations of soluble pertuzumab, trastuzumab,
IgG-Fab BsAb or IgG-scFv BsAb was measured by comparing
the linear slope (RUs/second) of first 40 seconds of the injection.
The stoichiometry of binding to each HER-2 epitope was deter-
mined based on the amount of mAb or BsAb necessary to fully
block HER-2 binding to either the pertuzumab or trastuzumab
surface. The pertuzumab and trastuzumab surfaces were both
regenerated by a double injection (5 mL) of 0.1 M glycine, pH 2
at a flow rate of 50 mL/min.
Binding kinetics for EGFR£CD3 BsAbs
Human CD3 and EGFR extracellular domain proteins were
prepared in-house. The CD3 construct was made as a single
chain e/g heterodimer as described,46 except it was expressed in
HEK293F, not bacteria, and contained a 25 amino acid (G4S)5
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linker between the e and g domains. The scCD3eg and sEGFR
proteins were diluted to 20 mg/mL in 10 mM acetate, pH 5.0
and immobilized to a CM5 chip surface (»2000 and »6000
RU, respectively) using the standard amine coupling protocols.
The EGFR£CD3 tandem scFv and tandem Fab molecules were
diluted into HBS-EP buffer (100, 75, 50, 37.5, 25, 12.5, 6.25
and 3.12 nM) and passed over the CD3eg or EGFR surfaces at
15 mL/min for 5 minutes. Dissociation was allowed to occur for
another 20 minutes. Surfaces were regenerated by raising the
flow rate to 50 mL/min and injecting 5 mL 0.1 M Glycine pH
2.0. All the curves were fit to a 1:1 Langmuir binding model to
obtain binding kinetics and equilibrium KDs. All experiments
were performed at 25C using HBS-EP as the running buffer.
Cell culture
N87 and A431 cells were obtained from the ATCC, tested
negative for mycoplasma, and cultured as described previously.14
Untreated, purified T cells from a human donor were purchased
from ALLCELLS (Cat#PB009–1F). The cells were thawed and
washed in 10% FBS (heat inactivated, Corning) plus 50 mg/ml
gentamicin (Gibco/Life Technologies) in RPMI 1640 media
(Corning). For pre-activated T cell assays, the T cells were added
to a 6 well plate or cell culture flask pre-coated with anti-CD3 at
5 mg/mL (BD Biosciences, clone UCHT1). After overnight
incubation at 37C in a 5% CO2 incubator, the T cells were
treated with 2.5 mg/mL anti-CD28 (BD Biosciences) and 5 ng/
mL IL-2 (R&D Systems). Every week the anti-CD3/anti-CD28/
IL-2 treatment was repeated to insure T cell activation, while IL-
2 added to all media during the expansion phase.
Flow cytometry
T cells were counted using a Countess II (Life Technologies).
They were spun down at by 1200 rpm for 8 minutes. The super-
natant was removed and the cells were resuspended in PBS and
adjusted to 1 £ 107 cells/mL. The cells were spun down again
and resuspended in flow cytometry blocking buffer (PBS w/2%
FBS, 0.05% NaN3, 10% normal goat serum or NGS, Life Tech-
nologies, and Human Fc block, BD Biosciences) for at least 15
minutes. Next, 50 mL cells are added to a 96-well plate (Corn-
ing, Cat#3799). Fluorescently labeled mAbs are added directly to
the cells at 50 mL/well and incubated for 45 minutes on ice. The
detection mAbs included a PE-mouse anti-human CD3 (BD,
Cat#555333), an APC-Cy7 mouse anti-human CD69
(BD, Cat#557756), an APC mouse anti-human CD25 (BD,
Cat#555434), Pacific Blue mouse anti-human CD8
(BD, Cat#558207), and an Alexa-488 mouse anti-human CD4
(BD, Cat#557695). The plates were spun for 4 minutes at
1500 rpm; supernatants were aspirated; and the cells were resus-
pended in 150 mL flow cytometry wash buffer (FCWB, PBS w/2%
FBS, 0.05% NaN3, and 10% NGS) at least 3 times. After the final
supernatant removal, cells were resuspended in 200 mL 1:1000 PI in
FCWB, covered with foil and sorted using an LSRII flow cytometer
acquiring with Diva version software (Beckton Dickonson). Analysis
was performed using FlowJo software. PI was from Molecular
Probes. Compensation was performed using OneComp eBeads from
eBioscience using themanufacturer’s protocol.
N87 gastric tumor cell proliferation assay
N87 cell proliferation studies were performed as described
previously with the modification that the IgG-Fab and IgG-scFv
were utilized.14
Pre-activated T cell redirected lysis of A431 carcinoma cells
A431 tumor cells were lifted using Accutase

(Innovative Cell
Technologies) and pre-stained with CSFE according to the
CSFE/7-AAD kit manufacturer’s protocols (abcam,
Cat#ab133073). After culturing between 4–6 hrs with pre-acti-
vated T cells (10:1, Effector:Tumor cells) in the absence or pres-
ence of mAb or BsAb test articles, the A431 cells were lifted
again and stained with the DNA-intercalating dye 7-aminoacti-
nomycin (7-AAD) according to the kit protocols. Flow cytome-
try was performed on a LSRII instrument (BD Biosciences)
using an FL1 channel for CSFE and FL3 channel for 7-AAD.
Alternately, pre-activated T cell killing was assessed using the
Cell Titer Glo (Promega) cell viability assay. Briefly, A431
tumor cells cultured in RPMI, 10% FBS were lifted using 0.25%
trypsin-EDTA (Sigma) and seeded at a density of 5000 cells per
well overnight in 96 well tissue culture black isoplates with clear
bottoms (Perkin Elmer, cat#6005050) at 37C, 5% CO2. Pre-
activated T cells (described above) in RPMI, 10% FBS, 50 mg/
mL gentamicin were mixed with the test articles (mAbs and
BsAbs) and added to each well at a 10:1 T cell:tumor cell ratio
and incubated for 5 hours at 37C, 5% CO2. After incubation,
the plate is washed 3 times with serum-free RPMI to remove the
T cells. Next, CellTiter-Glo reagent is added and luciferase lumi-
nescent signal is measured to quantify the number of viable cells
remaining based on the amount of ATP present. Luminescence
was measured using an Envision instrument (Perkin Elmer). Test
articles demonstrating redirected lysis activity were fit to a stan-
dard 4 parameter sigmoidal equation to calculate the midpoint
concentration (EC50) leading to 50% specific lysis:
Y DAC B¡Að Þ
.1C 10 LogEC50¡Xð Þ  nð Þ/ ;
where A is the bottom of the curve, B is the top of the curve,
and n is the steepness of the sigmoidal slope of the transition also
known as the Hill Slope (GraphPad Prism Software).
Bulk T cell activation and redirected lysis of A431 cells
Non-pre-treated T cell redirected lysis experiments were per-
formed in a very similar fashion as the pre-activated T cells redir-
ected lysis experiments with the following exceptions. T cells
were thawed in RPMI/10% FBS/50 mg/mL gentamicin, quanti-
fied, and directly mixed with the test articles (mAbs and BsAbs)
before adding them to A431 tumor cells (previously seeded over-
night) as described above at a 10:1 T cell:A431 cell ratio. The
cells were incubated for 48 hours. After incubation, soluble T
cells were collected for flow cytometric analysis of CD4, CD8,
CD69, and CD25 by washing with serum-free RPMI (at least
3 times). A431 lysis was measured by adding CellTiter-Glo
480 Volume 7 Issue 3mAbs
(Promega) and measuring the luciferase activity as described
above for the pre-activated T cell redirected lysis experiments.
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